The Federal Public Prosecutor's Office (MPF) wants the Federal Council of Medicine to explain the restriction on the prescription of cannabidiol.
The Federal Council of Medicine will have 15 days to respond to questions from the Federal Public Prosecutor's Office regarding the restriction of prescription of the medication to only three diseases.
247 - The Federal Public Prosecutor's Office (MPF) has opened an investigation to look into a measure by the Federal Council of Medicine (CFM) that restricts the use of... cannabidiol (CBD), a compound made from the cannabis sativa plant (marijuana), is used only for the treatment of childhood and adolescent epilepsy associated with Dravet and Lennox-Gastaut syndromes and Tuberous Sclerosis Complex, leaving behind diseases such as Alzheimer's or Parkinson's.
>>> Paulo Teixeira calls for the annulment of a resolution that limits the prescription of cannabidiol.
Furthermore, the Federal Public Prosecutor's Office wants the Federal Council of Medicine (CFM) to explain why the regulation still prohibits doctors from giving lectures and courses on the use of this and other cannabis-derived products outside of a scientific setting.
According to a report by newspaper According to Folha de S. Paulo, the Federal Public Prosecutor's Office (MPF) has requested documents from the Federal Council of Medicine (CFM) that demonstrate the scientific evidence supporting the recent regulation. The deadline for a response is 15 days.
Subscribe to 247, Support via Pix, Subscribe to TV 247, in the channel Cuts 247 and watch: